Nektar Therapeutics (NASDAQ:NKTR) Q2 2025 Earnings Conference Call August 7, 2025 5:00 PM ET
Company Participants
Howard W. Robin – CEO, President & Director
Jonathan Zalevsky – Senior VP and Chief Research & Development Officer
Korin Franklin – Corporate Participant
Sandra A. Gardiner – CFO and Principal Financial & Accounting Officer
Conference Call Participants
Alexandra V. Ramsey – William Blair & Company L.L.C., Research Division
Cha Cha Yang – Jefferies LLC, Research Division
Cheng Li – Oppenheimer & Co. Inc., Research Division
Jessica Macomber Fye – JPMorgan Chase & Co, Research Division
Julian Reed Harrison – BTIG, LLC, Research Division
Mayank Mamtani – B. Riley Securities, Inc., Research Division
Yasmeen Rahimi – Piper Sandler & Co., Research Division
Yu He – H.C. Wainwright & Co, LLC, Research Division
Operator
Welcome to the Nektar Therapeutics Second Quarter 2025 Financial Results Conference Call. [Operator Instructions] Please be advised that today’s conference is being recorded.
I would now like to hand the conference over to Korin Franklin from Nektar Therapeutics Investor Relations to kick things off. Please go ahead.
Korin Franklin
Thank you, and good afternoon, everyone. Thank you for joining us today. On the call today are Howard Robin, our President and Chief Executive Officer; Dr. Jonathan Zalevsky, our Chief Research and Development Officer; and Sandra Gardiner, our Chief Financial Officer. Dr. Brian Kotzin, our Chief Medical Officer, will also be available during the question-and-answer session.
On today’s call, we expect to make forward-looking statements regarding our business, including statements regarding the therapeutic potential of and future development and regulatory plans for rezpegaldesleukin and our other drug candidates, the timing and plans for future clinical data presentations and other statements regarding the future of our business.
Because forward-looking statements relate to the future, they are subject to uncertainties and risks that are difficult
#Nektar #Therapeutics #NKTR #Earnings #Call #Transcript